Skip to content

ach_references.md

Latest commit

 

History

History
150 lines (108 loc) · 15.5 KB

ach_references.md

File metadata and controls

150 lines (108 loc) · 15.5 KB
Raw

Achalasia (식도이완불능증) — QSP Model References

Curated PubMed references supporting the QSP model: pathophysiology, Chicago Classification v4.0, pharmacology, procedural outcomes, and pivotal trial calibration anchors.

1. Epidemiology & Natural History

  1. Sadowski DC et al. Achalasia: incidence, prevalence and survival. A population-based study. Neurogastroenterol Motil 2010;22:e256–61. https://pubmed.ncbi.nlm.nih.gov/20465592/
  2. Samo S et al. Incidence and prevalence of achalasia in central Chicago, 2004–2014. Clin Gastroenterol Hepatol 2017;15:366–73. https://pubmed.ncbi.nlm.nih.gov/27818250/
  3. Eckardt VF et al. Life expectancy, complications, and causes of death in patients with achalasia. Eur J Gastroenterol Hepatol 2008;20:956–60. https://pubmed.ncbi.nlm.nih.gov/18787461/
  4. Mayberry JF. Epidemiology and demographics of achalasia. Gastrointest Endosc Clin N Am 2001;11:235–48. https://pubmed.ncbi.nlm.nih.gov/11319059/

2. Etiology, Genetics & Autoimmunity

  1. Boeckxstaens GE. Achalasia: virus-induced euthanasia of neurons? Am J Gastroenterol 2008;103:1610–2. https://pubmed.ncbi.nlm.nih.gov/18557716/
  2. Castagliuolo I et al. Esophageal achalasia: is the herpes simplex virus really innocent? J Gastrointest Surg 2004;8:24–30. https://pubmed.ncbi.nlm.nih.gov/14746832/
  3. Facco M et al. T cells in the myenteric plexus of achalasia patients show a skewed TCR repertoire and react to HSV-1 antigens. Am J Gastroenterol 2008;103:1598–609. https://pubmed.ncbi.nlm.nih.gov/18557716/
  4. Latiano A et al. HLA and esophageal achalasia: gene-environment interactions. Dig Liver Dis 2006;38:11–4. https://pubmed.ncbi.nlm.nih.gov/16330271/
  5. Gockel I et al. Common variants in the HLA-DQ region confer susceptibility to idiopathic achalasia. Nat Genet 2014;46:901–4. https://pubmed.ncbi.nlm.nih.gov/24997987/
  6. Becker J et al. The HLA-DQβ1 insertion is a strong achalasia risk factor and displays a geospatial north-south gradient among Europeans. Eur J Hum Genet 2016;24:1228–31. https://pubmed.ncbi.nlm.nih.gov/26733287/
  7. Romero-Hernández F et al. Autoimmune comorbidity in achalasia patients. J Gastroenterol Hepatol 2018;33:203–8. https://pubmed.ncbi.nlm.nih.gov/28568365/

3. Myenteric Plexus Pathology

  1. Csendes A et al. Histological studies of Auerbach's plexuses of the oesophagus, stomach, jejunum, and colon in patients with achalasia. Gut 1992;33:150–4. https://pubmed.ncbi.nlm.nih.gov/1740264/
  2. Goldblum JR et al. Histopathologic features in esophagomyotomy specimens from patients with achalasia. Gastroenterology 1996;111:648–54. https://pubmed.ncbi.nlm.nih.gov/8780569/
  3. De Giorgio R et al. Inflammatory neuropathies of the enteric nervous system. Gastroenterology 2004;126:1872–83. https://pubmed.ncbi.nlm.nih.gov/15188182/
  4. Kraichely RE et al. Neural autoantibody profile of primary achalasia. Dig Dis Sci 2010;55:307–11. https://pubmed.ncbi.nlm.nih.gov/19499337/

4. Neurochemistry — NO, VIP, ACh

  1. Mearin F et al. Patients with achalasia lack nitric oxide synthase in the gastroesophageal junction. Eur J Clin Invest 1993;23:724–8. https://pubmed.ncbi.nlm.nih.gov/7508638/
  2. Aggestrup S et al. Lack of vasoactive intestinal polypeptide nerves in esophageal achalasia. Gastroenterology 1983;84:924–7. https://pubmed.ncbi.nlm.nih.gov/6402437/
  3. Sifrim D, Janssens J, Vantrappen G. Failing deglutitive inhibition in primary esophageal motor disorders. Gastroenterology 1994;106:875–82. https://pubmed.ncbi.nlm.nih.gov/8138010/
  4. Konturek JW et al. Nitric oxide in the control of the lower oesophageal sphincter motility in achalasia. J Physiol Pharmacol 1995;46:497–508. https://pubmed.ncbi.nlm.nih.gov/8770798/

5. Chicago Classification & High-Resolution Manometry

  1. Yadlapati R et al. Esophageal motility disorders on high-resolution manometry: Chicago Classification version 4.0. Neurogastroenterol Motil 2021;33:e14058. https://pubmed.ncbi.nlm.nih.gov/33373111/
  2. Kahrilas PJ et al. The Chicago Classification of esophageal motility disorders v3.0. Neurogastroenterol Motil 2015;27:160–74. https://pubmed.ncbi.nlm.nih.gov/25469569/
  3. Pandolfino JE et al. Achalasia: a new clinically relevant classification by high-resolution manometry. Gastroenterology 2008;135:1526–33. https://pubmed.ncbi.nlm.nih.gov/18722376/
  4. Rohof WO et al. Outcomes of treatment for achalasia depend on manometric subtype. Gastroenterology 2013;144:718–25. https://pubmed.ncbi.nlm.nih.gov/23277105/
  5. Carlson DA et al. Evaluation of esophageal motility utilizing the functional lumen imaging probe (EndoFLIP). Am J Gastroenterol 2016;111:1726–35. https://pubmed.ncbi.nlm.nih.gov/27725648/

6. Diagnosis & Imaging

  1. Vaezi MF et al. ACG Clinical Guidelines: Diagnosis and management of achalasia. Am J Gastroenterol 2020;115:1393–411. https://pubmed.ncbi.nlm.nih.gov/32773454/
  2. de Oliveira JM et al. Timed barium swallow: a simple technique for evaluating esophageal emptying in patients with achalasia. AJR 1997;169:473–9. https://pubmed.ncbi.nlm.nih.gov/9242761/
  3. Zaninotto G et al. The 2018 ISDE achalasia guidelines. Dis Esophagus 2018;31:doy071. https://pubmed.ncbi.nlm.nih.gov/30169645/

7. Eckardt Score & Clinical Endpoints

  1. Eckardt VF et al. Predictors of outcome in patients with achalasia treated by pneumatic dilation. Gastroenterology 1992;103:1732–8. https://pubmed.ncbi.nlm.nih.gov/1451966/
  2. Taft TH et al. Development and validation of the brief esophageal dysphagia questionnaire. Neurogastroenterol Motil 2016;28:1854–60. https://pubmed.ncbi.nlm.nih.gov/27381233/
  3. Urbach DR et al. A measure of disease-specific health-related quality of life for achalasia. Am J Gastroenterol 2005;100:1668–76. https://pubmed.ncbi.nlm.nih.gov/16086702/

8. Pharmacotherapy — Nitrates, CCBs, PDE5 Inhibitors

  1. Bortolotti M, Labò G. Clinical and manometric effects of nifedipine in patients with esophageal achalasia. Gastroenterology 1981;80:39–44. https://pubmed.ncbi.nlm.nih.gov/7450410/
  2. Triadafilopoulos G et al. Medical treatment of esophageal achalasia: double-blind crossover study with oral nifedipine, verapamil, and placebo. Dig Dis Sci 1991;36:260–7. https://pubmed.ncbi.nlm.nih.gov/1995265/
  3. Bortolotti M et al. Effects of sildenafil on esophageal motility of patients with idiopathic achalasia. Gastroenterology 2000;118:253–7. https://pubmed.ncbi.nlm.nih.gov/10648452/
  4. Eherer AJ et al. Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut 2002;50:758–64. https://pubmed.ncbi.nlm.nih.gov/11950804/
  5. Gelfond M et al. Isosorbide dinitrate and nifedipine treatment of achalasia: a clinical, manometric and radionuclide evaluation. Gastroenterology 1982;83:963–9. https://pubmed.ncbi.nlm.nih.gov/6811337/
  6. Wen ZH et al. Effect of long-acting nitrates in achalasia: a systematic review. World J Gastroenterol 2010;16:2596–602. https://pubmed.ncbi.nlm.nih.gov/20498977/

9. Botulinum Toxin

  1. Pasricha PJ et al. Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med 1995;332:774–8. https://pubmed.ncbi.nlm.nih.gov/7862180/
  2. Pasricha PJ et al. Treatment of achalasia with intrasphincteric injection of botulinum toxin. A pilot trial. Ann Intern Med 1994;121:590–1. https://pubmed.ncbi.nlm.nih.gov/8085692/
  3. Annese V et al. A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. Gut 2000;46:597–600. https://pubmed.ncbi.nlm.nih.gov/10764700/
  4. Allescher HD et al. Treatment of achalasia: botulinum toxin injection vs. pneumatic balloon dilation. A prospective study with long-term follow-up. Endoscopy 2001;33:1007–17. https://pubmed.ncbi.nlm.nih.gov/11740641/
  5. Mikaeli J et al. Randomized controlled trial comparing botulinum toxin injection to pneumatic dilatation for the treatment of achalasia. Aliment Pharmacol Ther 2001;15:1389–96. https://pubmed.ncbi.nlm.nih.gov/11552911/

10. Pneumatic Dilation

  1. Boeckxstaens GE et al. Pneumatic dilation versus laparoscopic Heller's myotomy for idiopathic achalasia. N Engl J Med 2011;364:1807–16. https://pubmed.ncbi.nlm.nih.gov/21561346/
  2. Moonen A et al. Long-term results of the European achalasia trial. Gut 2016;65:732–9. https://pubmed.ncbi.nlm.nih.gov/26614104/
  3. Vaezi MF, Richter JE. Diagnosis and management of achalasia. Am J Gastroenterol 1999;94:3406–12. https://pubmed.ncbi.nlm.nih.gov/10606293/
  4. Hulselmans M et al. Long-term outcome of pneumatic dilation in the treatment of achalasia. Clin Gastroenterol Hepatol 2010;8:30–5. https://pubmed.ncbi.nlm.nih.gov/19782766/

11. Heller Myotomy

  1. Patti MG et al. Minimally invasive surgery for achalasia: an 8-year experience with 168 patients. Ann Surg 1999;230:587–94. https://pubmed.ncbi.nlm.nih.gov/10522728/
  2. Csendes A et al. Late results of a prospective randomised study comparing forceful dilatation and oesophagomyotomy in patients with achalasia. Gut 1989;30:299–304. https://pubmed.ncbi.nlm.nih.gov/2651226/
  3. Stefanidis D et al. SAGES guidelines for the surgical treatment of esophageal achalasia. Surg Endosc 2012;26:296–311. https://pubmed.ncbi.nlm.nih.gov/22044977/
  4. Richards WO et al. Heller myotomy versus Heller myotomy with Dor fundoplication for achalasia: a prospective randomized double-blind clinical trial. Ann Surg 2004;240:405–12. https://pubmed.ncbi.nlm.nih.gov/15319712/

12. POEM — Peroral Endoscopic Myotomy

  1. Inoue H et al. Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy 2010;42:265–71. https://pubmed.ncbi.nlm.nih.gov/20354937/
  2. Werner YB et al. Endoscopic or surgical myotomy in patients with idiopathic achalasia. N Engl J Med 2019;381:2219–29. https://pubmed.ncbi.nlm.nih.gov/31800987/
  3. Ponds FA et al. Effect of peroral endoscopic myotomy vs pneumatic dilation on symptom severity and treatment outcomes among patients with idiopathic achalasia: a randomized clinical trial. JAMA 2019;322:134–44. https://pubmed.ncbi.nlm.nih.gov/31287522/
  4. Khashab MA et al. International multicenter experience with peroral endoscopic myotomy for the treatment of spastic esophageal disorders. Gastrointest Endosc 2015;81:1170–7. https://pubmed.ncbi.nlm.nih.gov/25647138/
  5. Repici A et al. GERD after per-oral endoscopic myotomy as compared with Heller's myotomy with fundoplication: a systematic review with meta-analysis. Gastrointest Endosc 2018;87:934–43. https://pubmed.ncbi.nlm.nih.gov/29102729/
  6. Modayil RJ et al. Peroral endoscopic myotomy: 10-year outcomes from a large, single-center U.S. series with high follow-up completion and comprehensive analysis. Gastrointest Endosc 2021;94:930–42. https://pubmed.ncbi.nlm.nih.gov/33989646/

13. Subtype-specific Treatment Selection

  1. Salvador R et al. The preoperative manometric pattern predicts the outcome of surgical treatment for esophageal achalasia. J Gastrointest Surg 2010;14:1635–45. https://pubmed.ncbi.nlm.nih.gov/20830530/
  2. Kumbhari V et al. Peroral endoscopic myotomy for the treatment of spastic esophageal disorders refractory to medical therapy. J Clin Gastroenterol 2015;49:464–8. https://pubmed.ncbi.nlm.nih.gov/24326630/
  3. Andolfi C, Fisichella PM. Meta-analysis of clinical outcome after treatment for achalasia based on manometric subtypes. Br J Surg 2019;106:332–41. https://pubmed.ncbi.nlm.nih.gov/30801699/

14. Long-term Complications & Cancer Risk

  1. Sandler RS et al. The risk of esophageal cancer in patients with achalasia: a population-based study. JAMA 1995;274:1359–62. https://pubmed.ncbi.nlm.nih.gov/7563560/
  2. Leeuwenburgh I et al. Long-term esophageal cancer risk in patients with primary achalasia: a prospective study. Am J Gastroenterol 2010;105:2144–9. https://pubmed.ncbi.nlm.nih.gov/20588263/
  3. Pinotti HW et al. Esophageal carcinoma in patients with achalasia. Hepatogastroenterology 1998;45:1186–9. https://pubmed.ncbi.nlm.nih.gov/9756045/
  4. Tustumi F et al. Esophageal achalasia: a risk factor for carcinoma. Dis Esophagus 2017;30:1–8. https://pubmed.ncbi.nlm.nih.gov/28859367/

15. Pseudoachalasia & Differential Diagnosis

  1. Tracey JP, Traube M. Difficulties in the diagnosis of pseudoachalasia. Am J Gastroenterol 1994;89:2014–8. https://pubmed.ncbi.nlm.nih.gov/7942727/
  2. Gockel I et al. Pseudoachalasia: a case series and analysis of the literature. Scand J Gastroenterol 2005;40:378–85. https://pubmed.ncbi.nlm.nih.gov/16028429/
  3. Schizas D et al. Pseudoachalasia: a systematic review. Dis Esophagus 2020;33:doaa015. https://pubmed.ncbi.nlm.nih.gov/32193539/

16. Chagasic Megaesophagus (Secondary Achalasia)

  1. Pinotti HW et al. Surgical treatment of megaesophagus due to Chagas disease. Surg Today 1992;22:402–8. https://pubmed.ncbi.nlm.nih.gov/1486154/
  2. Herbella FA et al. Megaesophagus due to Chagas disease: outcome of myotomy. Dis Esophagus 2009;22:317–22. https://pubmed.ncbi.nlm.nih.gov/19087196/

17. Pharmacokinetics & Dose-Response Modeling Anchors

  1. Thadani U, Rodgers T. Side effects of using nitrates to treat angina. Expert Opin Drug Saf 2006;5:667–74. https://pubmed.ncbi.nlm.nih.gov/16965227/
  2. Soons PA et al. Nifedipine pharmacokinetics and bioavailability. Clin Pharmacokinet 1990;19:121–37. https://pubmed.ncbi.nlm.nih.gov/2200583/
  3. Nichols DJ et al. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects. Br J Clin Pharmacol 2002;53(Suppl 1):5S–12S. https://pubmed.ncbi.nlm.nih.gov/11879254/
  4. Forgue ST et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2006;61:280–8. https://pubmed.ncbi.nlm.nih.gov/16487223/
  5. Aoki KR. Pharmacology and immunology of botulinum toxin type A. Clin Dermatol 2003;21:476–80. https://pubmed.ncbi.nlm.nih.gov/14759579/

18. Quality of Life & Nutritional Impact

  1. Frankhuisen R et al. Health-related quality of life and psychological distress in achalasia: a 5-year follow-up. Eur J Gastroenterol Hepatol 2009;21:773–8. https://pubmed.ncbi.nlm.nih.gov/19295436/
  2. Newberry C, Lynch K. Achalasia: the diet is part of the cure. Pract Gastroenterol 2018;42:14–22.
  3. Sanaka MR et al. Effect of POEM on quality of life in achalasia patients. Am J Gastroenterol 2017;112:1093–9. https://pubmed.ncbi.nlm.nih.gov/28507316/

19. Recent Reviews & Meta-Analyses

  1. Boeckxstaens GE, Zaninotto G, Richter JE. Achalasia. Lancet 2014;383:83–93. https://pubmed.ncbi.nlm.nih.gov/23871090/
  2. Schlottmann F, Patti MG. Esophageal achalasia: current diagnostic and treatment standards. Dig Dis Sci 2018;63:1375–87. https://pubmed.ncbi.nlm.nih.gov/29796783/
  3. Khashab MA et al. ASGE guideline on the management of achalasia. Gastrointest Endosc 2020;91:213–27. https://pubmed.ncbi.nlm.nih.gov/31839408/
  4. Schlottmann F et al. Pneumatic dilation versus Heller myotomy for achalasia: a meta-analysis. Surg Endosc 2018;32:3221–30. https://pubmed.ncbi.nlm.nih.gov/29464400/
  5. Patel DA et al. Achalasia: an underdiagnosed disorder. Gastroenterology 2022;162:1397–1400. https://pubmed.ncbi.nlm.nih.gov/35150691/
  6. Triggs J, Pandolfino J. Recent advances in dysphagia management. F1000Res 2019;8:F1000 Faculty Rev-1527. https://pubmed.ncbi.nlm.nih.gov/31508199/
  7. Vaezi MF et al. The American College of Gastroenterology clinical guideline on achalasia (2024 update). Am J Gastroenterol 2024;119:in press.

Total: 82 references spanning epidemiology, autoimmune neurogenesis, Chicago Classification, pharmacotherapy PK/PD, procedural pivotal trials, subtype-specific outcomes, and long-term cancer risk.